Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
27
TCRT Quote, Financials, Valuation and Earnings
Last price:
$1.92
Seasonality move
:
26.55%
Day range:
$1.90 - $2.03
52-week range:
$1.63 - $32.85
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.15x
Volume:
5K
Avg. volume:
28.5K
1-year change:
-73.6%
Market cap:
$3.1M
Revenue:
$5K
EPS (TTM):
-$7.41
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TCRT
Alaunos Therapeutics
|
-- | -- | -- | -- | -- |
|
AVXL
Anavex Life Sciences
|
-- | -$0.17 | -- | -72.73% | $35.47 |
|
GALT
Galectin Therapeutics
|
-- | -- | -- | -- | -- |
|
MBOT
Microbot Medical
|
-- | -$0.17 | -- | -32% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | -- |
|
SLS
SELLAS Life Sciences Group
|
-- | -$0.13 | -- | -57.33% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TCRT
Alaunos Therapeutics
|
$1.96 | -- | $3.1M | -- | $0.00 | 0% | -- |
|
AVXL
Anavex Life Sciences
|
$10.87 | $35.47 | $921.9M | -- | $0.00 | 0% | -- |
|
GALT
Galectin Therapeutics
|
$0.84 | -- | $52.8M | -- | $0.00 | 0% | -- |
|
MBOT
Microbot Medical
|
$1.00 | -- | $16.9M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$0.38 | -- | $4.6M | -- | $0.00 | 0% | 1.49x |
|
SLS
SELLAS Life Sciences Group
|
$0.93 | -- | $65.4M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TCRT
Alaunos Therapeutics
|
-- | 2.640 | -- | 2.72x |
|
AVXL
Anavex Life Sciences
|
-- | 3.153 | -- | -- |
|
GALT
Galectin Therapeutics
|
-- | -3.116 | -- | -- |
|
MBOT
Microbot Medical
|
-- | 2.795 | -- | -- |
|
OGEN
Oragenics
|
-- | 5.927 | -- | -- |
|
SLS
SELLAS Life Sciences Group
|
-- | 0.853 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TCRT
Alaunos Therapeutics
|
-- | -$1.2M | -189.69% | -189.69% | -28225% | -$781K |
|
AVXL
Anavex Life Sciences
|
-- | -$14.3M | -- | -- | -- | -$6.7M |
|
GALT
Galectin Therapeutics
|
-- | -$9.1M | -- | -- | -- | -$8.5M |
|
MBOT
Microbot Medical
|
-- | -$3.3M | -- | -- | -- | -$2.8M |
|
OGEN
Oragenics
|
-- | -$2.4M | -- | -- | -- | -$2M |
|
SLS
SELLAS Life Sciences Group
|
-- | -$7.3M | -- | -- | -- | -$7.8M |
Alaunos Therapeutics vs. Competitors
-
Which has Higher Returns TCRT or AVXL?
Anavex Life Sciences has a net margin of -28225% compared to Alaunos Therapeutics's net margin of --. Alaunos Therapeutics's return on equity of -189.69% beat Anavex Life Sciences's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TCRTAlaunos Therapeutics-- -$0.70 $3.8M AVXLAnavex Life Sciences-- -$0.14 -- -
What do Analysts Say About TCRT or AVXL?
Alaunos Therapeutics has a consensus price target of --, signalling upside risk potential of 10385.22%. On the other hand Anavex Life Sciences has an analysts' consensus of $35.47 which suggests that it could grow by 226.33%. Given that Alaunos Therapeutics has higher upside potential than Anavex Life Sciences, analysts believe Alaunos Therapeutics is more attractive than Anavex Life Sciences.
Company Buy Ratings Hold Ratings Sell Ratings TCRTAlaunos Therapeutics0 0 0 AVXLAnavex Life Sciences2 0 0 -
Is TCRT or AVXL More Risky?
Alaunos Therapeutics has a beta of -0.444, which suggesting that the stock is 144.433% less volatile than S&P 500. In comparison Anavex Life Sciences has a beta of 0.729, suggesting its less volatile than the S&P 500 by 27.09%.
-
Which is a Better Dividend Stock TCRT or AVXL?
Alaunos Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anavex Life Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alaunos Therapeutics pays -- of its earnings as a dividend. Anavex Life Sciences pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TCRT or AVXL?
Alaunos Therapeutics quarterly revenues are $4K, which are larger than Anavex Life Sciences quarterly revenues of --. Alaunos Therapeutics's net income of -$1.1M is higher than Anavex Life Sciences's net income of -$11.6M. Notably, Alaunos Therapeutics's price-to-earnings ratio is -- while Anavex Life Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alaunos Therapeutics is -- versus -- for Anavex Life Sciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCRTAlaunos Therapeutics-- -- $4K -$1.1M AVXLAnavex Life Sciences-- -- -- -$11.6M
-
Which has Higher Returns TCRT or GALT?
Galectin Therapeutics has a net margin of -28225% compared to Alaunos Therapeutics's net margin of --. Alaunos Therapeutics's return on equity of -189.69% beat Galectin Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TCRTAlaunos Therapeutics-- -$0.70 $3.8M GALTGalectin Therapeutics-- -$0.18 -- -
What do Analysts Say About TCRT or GALT?
Alaunos Therapeutics has a consensus price target of --, signalling upside risk potential of 10385.22%. On the other hand Galectin Therapeutics has an analysts' consensus of -- which suggests that it could grow by 1208.59%. Given that Alaunos Therapeutics has higher upside potential than Galectin Therapeutics, analysts believe Alaunos Therapeutics is more attractive than Galectin Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings TCRTAlaunos Therapeutics0 0 0 GALTGalectin Therapeutics0 0 0 -
Is TCRT or GALT More Risky?
Alaunos Therapeutics has a beta of -0.444, which suggesting that the stock is 144.433% less volatile than S&P 500. In comparison Galectin Therapeutics has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.07%.
-
Which is a Better Dividend Stock TCRT or GALT?
Alaunos Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Galectin Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alaunos Therapeutics pays -- of its earnings as a dividend. Galectin Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TCRT or GALT?
Alaunos Therapeutics quarterly revenues are $4K, which are larger than Galectin Therapeutics quarterly revenues of --. Alaunos Therapeutics's net income of -$1.1M is higher than Galectin Therapeutics's net income of -$11.2M. Notably, Alaunos Therapeutics's price-to-earnings ratio is -- while Galectin Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alaunos Therapeutics is -- versus -- for Galectin Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCRTAlaunos Therapeutics-- -- $4K -$1.1M GALTGalectin Therapeutics-- -- -- -$11.2M
-
Which has Higher Returns TCRT or MBOT?
Microbot Medical has a net margin of -28225% compared to Alaunos Therapeutics's net margin of --. Alaunos Therapeutics's return on equity of -189.69% beat Microbot Medical's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TCRTAlaunos Therapeutics-- -$0.70 $3.8M MBOTMicrobot Medical-- -$0.20 -- -
What do Analysts Say About TCRT or MBOT?
Alaunos Therapeutics has a consensus price target of --, signalling upside risk potential of 10385.22%. On the other hand Microbot Medical has an analysts' consensus of -- which suggests that it could grow by 602.11%. Given that Alaunos Therapeutics has higher upside potential than Microbot Medical, analysts believe Alaunos Therapeutics is more attractive than Microbot Medical.
Company Buy Ratings Hold Ratings Sell Ratings TCRTAlaunos Therapeutics0 0 0 MBOTMicrobot Medical0 0 0 -
Is TCRT or MBOT More Risky?
Alaunos Therapeutics has a beta of -0.444, which suggesting that the stock is 144.433% less volatile than S&P 500. In comparison Microbot Medical has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.938%.
-
Which is a Better Dividend Stock TCRT or MBOT?
Alaunos Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Microbot Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alaunos Therapeutics pays -- of its earnings as a dividend. Microbot Medical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TCRT or MBOT?
Alaunos Therapeutics quarterly revenues are $4K, which are larger than Microbot Medical quarterly revenues of --. Alaunos Therapeutics's net income of -$1.1M is higher than Microbot Medical's net income of -$3.2M. Notably, Alaunos Therapeutics's price-to-earnings ratio is -- while Microbot Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alaunos Therapeutics is -- versus -- for Microbot Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCRTAlaunos Therapeutics-- -- $4K -$1.1M MBOTMicrobot Medical-- -- -- -$3.2M
-
Which has Higher Returns TCRT or OGEN?
Oragenics has a net margin of -28225% compared to Alaunos Therapeutics's net margin of --. Alaunos Therapeutics's return on equity of -189.69% beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TCRTAlaunos Therapeutics-- -$0.70 $3.8M OGENOragenics-- -$0.38 -- -
What do Analysts Say About TCRT or OGEN?
Alaunos Therapeutics has a consensus price target of --, signalling upside risk potential of 10385.22%. On the other hand Oragenics has an analysts' consensus of -- which suggests that it could grow by 23709.52%. Given that Oragenics has higher upside potential than Alaunos Therapeutics, analysts believe Oragenics is more attractive than Alaunos Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings TCRTAlaunos Therapeutics0 0 0 OGENOragenics0 0 0 -
Is TCRT or OGEN More Risky?
Alaunos Therapeutics has a beta of -0.444, which suggesting that the stock is 144.433% less volatile than S&P 500. In comparison Oragenics has a beta of 0.434, suggesting its less volatile than the S&P 500 by 56.551%.
-
Which is a Better Dividend Stock TCRT or OGEN?
Alaunos Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alaunos Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TCRT or OGEN?
Alaunos Therapeutics quarterly revenues are $4K, which are larger than Oragenics quarterly revenues of --. Alaunos Therapeutics's net income of -$1.1M is higher than Oragenics's net income of -$2.5M. Notably, Alaunos Therapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alaunos Therapeutics is -- versus 1.49x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCRTAlaunos Therapeutics-- -- $4K -$1.1M OGENOragenics1.49x -- -- -$2.5M
-
Which has Higher Returns TCRT or SLS?
SELLAS Life Sciences Group has a net margin of -28225% compared to Alaunos Therapeutics's net margin of --. Alaunos Therapeutics's return on equity of -189.69% beat SELLAS Life Sciences Group's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TCRTAlaunos Therapeutics-- -$0.70 $3.8M SLSSELLAS Life Sciences Group-- -$0.10 -- -
What do Analysts Say About TCRT or SLS?
Alaunos Therapeutics has a consensus price target of --, signalling upside risk potential of 10385.22%. On the other hand SELLAS Life Sciences Group has an analysts' consensus of -- which suggests that it could grow by 527.58%. Given that Alaunos Therapeutics has higher upside potential than SELLAS Life Sciences Group, analysts believe Alaunos Therapeutics is more attractive than SELLAS Life Sciences Group.
Company Buy Ratings Hold Ratings Sell Ratings TCRTAlaunos Therapeutics0 0 0 SLSSELLAS Life Sciences Group0 0 0 -
Is TCRT or SLS More Risky?
Alaunos Therapeutics has a beta of -0.444, which suggesting that the stock is 144.433% less volatile than S&P 500. In comparison SELLAS Life Sciences Group has a beta of 2.391, suggesting its more volatile than the S&P 500 by 139.11%.
-
Which is a Better Dividend Stock TCRT or SLS?
Alaunos Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SELLAS Life Sciences Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alaunos Therapeutics pays -- of its earnings as a dividend. SELLAS Life Sciences Group pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TCRT or SLS?
Alaunos Therapeutics quarterly revenues are $4K, which are larger than SELLAS Life Sciences Group quarterly revenues of --. Alaunos Therapeutics's net income of -$1.1M is higher than SELLAS Life Sciences Group's net income of -$7.1M. Notably, Alaunos Therapeutics's price-to-earnings ratio is -- while SELLAS Life Sciences Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alaunos Therapeutics is -- versus -- for SELLAS Life Sciences Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCRTAlaunos Therapeutics-- -- $4K -$1.1M SLSSELLAS Life Sciences Group-- -- -- -$7.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
